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(HR 1.512; CI: 1.333−1.716; p< 0.001), ranging to 13% with oxybutynin IR (HR 2.315; CI: 
2.093−2.561; p< 0.001). Median number of days on therapy with mirabegron was 183 
(treatment-experienced) and 129 (treatment-naïve), compared with 67−120 and 34−90 
days with antimuscarinics, respectively. Mean adherence overall was 68% with mira-
begron vs 39−55% with antimuscarinics (each p< 0.05 vs mirabegron). ConClusions: 
Patients treated with mirabegron had improved persistence and adherence over anti-
muscarinics. While differences in patient characteristics among the OAB drugs were 
accounted for within the model, results should be viewed in the light of the likely 
characteristics of patients started on any new medication to the market; hence this 
sample may not be reflective of more mature usage.
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objeCtives: The frequency of side effects in the treatment with anticholinergic 
drugs are well described in a number of previous studies. However, little is known 
about the impact of side effects on therapy discontinuation. The aim of the pre-
sent study was to estimate the frequency of glaucoma in association with urinary 
incontinence therapy begin and the impact of glaucoma diagnosis on the therapy 
discontinuation based on real life data. Methods: Data from Disease Analyzer 
database including 988 general, 95 urologist and 203 gynecologist practices were 
used. 26,834 patients (17,125 female and 9,709 male) were identified to have received 
a first-time anticholinergic prescription of UI, namely darifenacin, fesoterodine, 
oxybutynin, propiverine, solifenacin, tolterodine or trospium. Co-variates studied 
included demographic data, concomitant diagnoses and potential drug-induced 
side-effects. Glaucoma (H40) was defined as strict indication for the use of anticho-
linergic drugs. A Cox proportional hazard regression model was used to estimate the 
relationship between non-persistence and the diagnosis of glaucoma for up to 36 
months. Results: The proportion of patients that were diagnosed with glaucoma 
during the time of treatment was very similar in each of the study substances. 
32 - 38 % of patients received a referral to an ophthalmologist and 0.3 - 1.2 % of 
patients were first time diagnosed with glaucoma. Not surprisingly, there was a 
highly increased risk for treatment discontinuation in patients having glaucoma 
(HR: 1.46; p < 0.0001). ConClusions: Overall, the potential side effects including 
the aggravation of diagnosed glaucoma that were registered in the database were 
rarer than in clinical trials; most likely they were under-reported due to the nature 
of the registry. However, there was a significant impact of glaucoma on therapy 
discontinuation. This finding should be taken into account in clinical practice for 
the use of anticholinergic drugs in patients suffering from glaucoma.
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objeCtives: This study aimed to assess the health-related quality of life (HRQOL) 
of multiethnic Asian end-stage renal disease (ESRD) patients treated with dialy-
sis and to identify factors associated with the HRQOL of those patients. The role 
of dialysis modality was also explored. Methods: Data used in this study were 
from two cross-sectional surveys of Singaporean ESRD patients on haemodialysis 
[HD] or peritoneal dialysis [PD]. In both surveys, participants were assessed using 
the Kidney Disease Quality of Life (KDQOL) instrument and questions assessing 
socio-demographic characteristics. Clinical data including co-morbidities, albu-
min level, haemoglobin level, and dialysis-related variables (e. g. dialysis vintage 
and dialysis adequacy) were retrieved from medical records. The 36-item KDQOL 
(KDQOL-36) was used to generate three summary scores (physical component sum-
mary [PCS], mental component summary [MCS], kidney disease component sum-
mary [KDCS]) and two health utility scores (Short Form 6-Dimension [SF-6D] and 
EuroQol 5-Dimension [EQ-5D]). Multivariate analysis was performed to examine the 
association of demographic, social and clinical variables with each of the HRQOL 
scores. Results: Five hundred and two patients were included in the study (HD: 
236, PD: 266; mean age: 57.1 years; female: 47.6%). The mean (standard deviation 
[SD]) were PCS 37.9 (9.7), MCS 46.4 (10.8) and KDCS 57.6 (18.1); the mean (SD) of the 
health utility were 0.66 (0.12) for SF-6D and 0.60 (0.21) for EQ-5D. In multivariate 
regression analysis, factors found to be significantly associated with better HRQOL 
included: fewer co-morbidities, higher albumin level, and higher haemoglobin 
level with PCS and EQ-5D; higher albumin level with SF-6D; longer dialysis vin-
tage with MCS; and Malay ethnicity, PD modality, and longer dialysis vintage with 
KDCS. ConClusions: Socio-demographic and clinical factors are both associated 
with HRQOL in ESRD patients on dialysis in Singapore. Dialysis modality has no 
impact on the health utility of those patients.
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objeCtives: Anticholinergics drugs (ACHD) are an established first-line pharmaco-
logical therapy for overactive bladder (OAB). Despite the fact that many patients cycle 
through multiple ACHD, there is limited evidence on the relationship between the bur-
den on secondary (hospital) care and these patients whose OAB is inadequately man-
aged with ACHD. The objective of this study was to analyse the variation in health care 
burden in secondary care of patients who cycle through multiple ACHD. Methods: A 
retrospective observational study was conducted to examine the relationship between 
health care burden and number of prior ACHD with each ACHD switch. Data was 
extracted from the Hospital Episode Statistics (HES) database and 3,059 GP practices 
for patients with a diagnosis for OAB, or any of the symptoms of OAB (frequency, 
urgency, incontinence or nocturia) and with at least one prescription for an ACHD 
between April 2007 and March 2013. Treatment activity and cost burden (including 
burden associated with comorbid conditions) were analysed following initiation of 
the second and the third ACHD and compared to the same cohort from the point at 
which they had received the first ACHD. All costs were calculated by applying national 
health service (NHS) tariff prices to treatment activity. Results: Overall, the number 
of patients identified was 13,117. Our analysis showed that there were increases of 
70%, 40% and 10% in inpatient, outpatient and emergency settings respectively from 
the initial ACHD prescription to 3+ ACHD. This led to an increase in overall health 
care costs of 30% from the first to 3+ ACHD or £197 (£642 to £839) per patient over the 
investigation period. ConClusions: OAB patients who are inadequately managed 
with ACHD place an increased burden on hospital resources. These findings empha-
size the importance of identifying alternative ways to treat these patients to address 
the cumulative burden they place on health care systems.
Urinary/KiDney DisorDers – Patient-reported outcomes & Patient Preference 
studies
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objeCtives: ACCEPT® is a 32-items self-administered questionnaire recently vali-
dated to measure patient acceptance to treatment. Acceptance was defined as the 
balance between treatment advantages and disadvantages as rated by the patient and 
may help predict adherence. The objective was to evaluate the relation between early 
Acceptance and Compliance in liver- and kidney-transplanted patients converted 
to once-daily tacrolimus (TAC-OD). Methods: 6-month observational, prospective, 
longitudinal, multicenter study conducted by 23 hepatologists and 56 nephrologists 
in France. 1106 adult patients with kidney and/or liver transplant, initiating TAC-OD 
during post-transplant follow-up were included. Acceptance and compliance were 
assessed 3 and 6 months after TAC-OD initiation using ACCEPT® and Compliance 
Evaluation Test questionnaires. Results: Data from 271 liver-, 824 kidney- and 11 
liver+kidney-transplanted patients were analyzed. Mean age was 52.4 (±13.2) years. 
61.5% of patients were male. Mean time between graft and TAC-OD initiation was 
5.0 (±4.9) years. Mean general acceptance score (range: 0-100) at month 3 was 75.4 
(±26.5). At month 6, 25.5% of patients had good treatment compliance, 68.0% minor 
non-compliance and 6.5% were non-compliant. Higher general acceptance score 
at month 3 was significantly associated with better compliance at month 6 (good 
compliance: 85.2±20.7, minor non-compliance: 74.5±26.7, non-compliant: 68.0±29.6, 
p< 0.001). 3-month general acceptance score was particularly low in patients who 
specified at month 6 having ‘omitted to take their treatment this morning’ (N= 4, 
mean: 41.7±44.1) or ‘ever forgotten to take their treatment because their memory was 
failing’ (N= 53, mean: 69.5±29.7). Although not significant, the 17 patients who discon-
tinued TAC-OD before 6 months had lower 3-month mean general acceptance score 
(64.6±36.5 vs. 75.7±25.9 in patients still treated with TAC-OD). ConClusions: This 
study highlighted a strong association between early Acceptance and late Compliance 
to TAC-OD. Further investigations are needed to explore how early detection of low 
acceptance can help patient management and improve long-term outcomes.
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objeCtives: To compare persistence and adherence with mirabegron versus anti-
muscarinic treatment for overactive bladder (OAB). Methods: This was an explora-
tory analysis of retrospective claims data from the largest Private Drug Plan database 
in Canada. Patients aged ≥ 18y who had a first prescription claim for a target medica-
tion during a four-month index period in 2013 were identified. A six-month look-back 
was used to categorize patients as ‘treatment-naïve’ (no claims for OAB medication) 
or ‘treatment-experienced’ (≥ 1 prior medication) during this time. Time to end of 
persistence (defined by a maximum gap in therapy of 30 days or switching to another 
medication) and adherence (calculated by medication possession ratio) were analyzed 
after six months. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated 
for mirabegron versus each antimuscarinic, using Cox proportional hazards mod-
eling. Results: Data were analyzed for 13,391 patients (mirabegron, n= 993). In the 
treatment-experienced cohort, six-month persistence was highest with mirabegron 
(51%), followed by solifenacin (39%) (HR 1.383; CI: 1.109−1.726; p= 0.004), ranging to 18% 
with oxybutynin IR (HR 2.488; CI: 1.961−3.157; p< 0.001). In the treatment-naïve cohort, 
persistence was also highest with mirabegron (40%), followed by fesoterodine (24%) 
